SEC Form 4 · accession 0001209191-18-048858
Ovid Therapeutics Inc. · OVID
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dirk Haasner
Officer — SVP, Global Regulatory Affairs
Period of report
Aug 27, 2018
Accepted (ET)
Aug 29, 2018 · 6:24 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001636651
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $6.40 | Aug 27, 2018 | A | 22,500 | A | — | Aug 27, 2028 | Common Stock | 22,500 | 22,500 | D |
Explanation of responses
- F1The option, representing a right to purchase a total of 22,500 shares becomes exercisable in two equal annual installments beginning on August 27, 2019, subject to the Reporting Person's continued service through each such date.